Background: Glucocorticoids are the mainstay of treatment for autoimmune blistering diseases (AIBDs). The Glucocorticoid Toxicity Index (GTI) is a novel, outcome-based glucocorticoid-induced adverse effects monitoring instrument.
Objective: To investigate whether the GTI score was able to accurately quantify the glucocorticoid-induced toxicity in patients with AIBDs.
Methods: The prospective cohort study included patients with confirmed diagnoses of AIBDs (group1, currently receiving glucocorticoids; and group 2, had glucocorticoids ceased earlier). Data were collected minimally at baseline (V1) and 3 months (V2). Further data from patients who were able to complete the follow-up visits at 6 months (V3) and 12 months (V4) amid the COVID-19 pandemic were also included. GTI scores were calculated after data collection.
Results: Analysis of data from V1 and V2 found a linear correlation between GTI score and prednisone doses ( < .05) and a significant difference in GTI scores between group1 and group 2 ( < .05). Data from V3 and V4 suggested that GTI scores continued to rise progressively alongside increasing cumulative prednisone dose.
Limitations: Small sample size, further exacerbated by the COVID-19 pandemic. Single-center study.
Conclusion: The GTI sensitively and specifically captured the changes in glucocorticoids toxicity over time among patients with AIBDs. The GTI could be a feasible tool that can be used in future clinical trials as a glucocorticoid-induced toxicity outcome measure.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8760348 | PMC |
| http://dx.doi.org/10.1016/j.jdin.2021.09.003 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dyshidrosiform Bullous Pemphigoid: A Palmar Variant of a Common Disease.
Cureus
December 2024
Dermatology, Corewell Health Farmington Hills Hospital, Farmington Hills, USA.
Dyshidrosiform bullous pemphigoid (DBP) is a rare variant of bullous pemphigoid (BP) that mainly affects elderly patients and presents with tense bullae formation on the palms, soles, or both palms and soles. This case report describes an 87-year-old woman who was evaluated in the hospital for a month-long erythematous and pruritic rash on most of her body that eventually manifested into tense blisters on the palms. DBP can pose a challenge to clinicians as it can resemble a variety of different vesicular diseases.
View Article and Find Full Text PDFHospital Dermatology: Review of Research in 2023-2024.
Cutis
November 2024
Dr. Wei is from the Department of Dermatology, University of Washington, Seattle. Dr. Micheletti is from the Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Inpatient consultative dermatologists play a critical role in the care of hospitalized patients with skin disease. Our review of the 2023-2024 dermatology literature identified several areas of active investigation relevant to inpatient dermatology. In this article, we highlight advances in the understanding of severe cutaneous adverse drug reactions, diagnosis and prevention of skin and soft tissue infections, and management of autoimmune blistering diseases (AIBDs).
View Article and Find Full Text PDFAssociation of statins, gliptins, and antipsychotics with bullous pemphigoid: A case-control study in the Cretan population.
J Dermatol
January 2025
School of Medicine, University of Crete, Heraklion, Greece.
Bullous pemphigoid (BP) is an autoimmune blistering disorder predominantly affecting the elderly. Recently, many studies have shed light on the effect of specific drug intake and comorbidities on the development of BP. The purpose of this study was to investigate the association of specific drug class intake and comorbidities with the development of BP in the Cretan population.
View Article and Find Full Text PDFBullous pemphigoid and hypercoagulability: a review.
Expert Rev Clin Immunol
January 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.
Introduction: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies against hemidesmosomal proteins on basal membrane zone. The presence of a high incidence of thrombotic events has led to the identification of a hypercoagulable state in BP patients.
Area Covers: This review highlights the interactions between coagulation and immune-inflammatory responses based on the current literature available, as well as individual changes of characteristic coagulation parameters in BP.
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review.
Viruses
December 2024
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.
The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous vaccines are available on a global scale and are based on different mechanisms of action, including mRNA technology, viral vectors, inactive viruses, and subunit particles. Mass vaccination conducted worldwide has highlighted the potential development of side effects, including ones with skin involvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!